Post hoc exploratory analysis of rucaparib in patients with platinum-sensitive recurrent ovarian carcinoma from the randomized, placebo-controlled phase III study ARIEL3: Effect of a deleterious germline or no germline mutation on efficacy
Year: 2019
Type: article
Source: Gynecologic Oncology
Institutions: The University of Texas MD Anderson Cancer Center, University Health Network, Princess Margaret Cancer Centre, Fondazione IRCCS Istituto Nazionale dei Tumori, Memorial Sloan Kettering Cancer Center, Vall d'Hebron Hospital Universitari, Vall d'Hebron Institute of Oncology, St John of God Subiaco Hospital, European Institute of Oncology, Ottawa Hospital Research Institute, University of Manchester, The Christie NHS Foundation Trust, Università Cattolica del Sacro Cuore, Agostino Gemelli University Polyclinic, Istituti di Ricovero e Cura a Carattere Scientifico, Inserm, Institut Gustave Roussy, Florida Hospital Cancer Institute, Centro Oncológico de Galicia, Auckland City Hospital, The University of Queensland, Royal Brisbane and Women's Hospital, The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University, Royal Marsden NHS Foundation Trust, Institute of Cancer Research, Royal Marsden Hospital, Clovis Oncology (United States), University College London
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2955020054